Synthesis and Anti-Hepatoma Activities of U12 Derivatives Arresting G0/G1 Phase and Inducing Apoptosis by PI3K/AKT/mTOR Pathway

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Jan 21

PMID 35056164

Authors

Renjing Yang

Chunchun Du

Ting Cao

Guanghui Wang

Xin Jiang

Jun Gao

Ting Lin

Cuiling Sun

Rong Ding

Wenjing Tian

Haifeng Chen

Affiliations

Soon will be listed here.

Abstract

Ursodeoxycholic acid (UDCA) is a first-line clinical drug for the treatment of liver diseases. U12, a derivative of UDCA, showed effective anti-hepatoma activities in previous works. However, the low polarity and large doses limited the druglikeness of U12. In this study, the structural modification and optimization of U12 were further investigated and twelve U12 derivatives were synthesized by substitution, esterification and amidation reactions. The evaluation of the cytotoxicity of synthetic derivatives against hepatoma cell lines (HepG2) indicated that U12-I, U12a-d and U12h showed more effective cytotoxiceffects on the growth of HepG2 cells than U12, and the preliminary structure-activity relationship was discussed. Among them, U12a exhibited the most potent anti-hepatocellular carcinoma activity. Mechanism studies indicated that U12a inhibited HepG2 cell proliferation by arresting the G0/G1 phase, and suppressed the activation of the PI3K/AKT/mTOR pathway. Further studies showed that U12a induced HepG2 cells apoptosis through activating the caspase signaling pathway. Furthermore, U12a evidently inhibits the growth of HepG2-derived tumor xenografts in vivo without observable adverse effects. Thus, U12a might be considered as a promising candidate for the treatment of hepatocellular carcinoma.

References

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

Choi W, Choi J, Lee D, Shim J, Lim Y, Lee H . Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020; 4(7):1073-1086. PMC: 7327222. DOI: 10.1002/hep4.1523. View

Mou Z, Wang Y, Li Y . RETRACTED: Brazilein induces apoptosis and G1/G0 phase cell cycle arrest by up-regulation of miR-133a in human vestibular schwannoma cells. Exp Mol Pathol. 2019; 107:95-101. DOI: 10.1016/j.yexmp.2018.12.010. View

Centuori S, Martinez J . Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. Dig Dis Sci. 2014; 59(10):2367-80. PMC: 4163523. DOI: 10.1007/s10620-014-3190-7. View

Sheng X, Zhu P, Zhao Y, Zhang J, Li H, Zhao H . Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin. Recent Pat Anticancer Drug Discov. 2021; 16(1):54-65. DOI: 10.2174/1574892816666210201120324. View

Alberts D, Martinez M, Hess L, Einspahr J, Green S, Bhattacharyya A . Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005; 97(11):846-53. DOI: 10.1093/jnci/dji144. View

Sombetzki M, Fuchs C, Fickert P, Osterreicher C, Mueller M, Claudel T . 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol. 2014; 62(4):871-8. PMC: 4368108. DOI: 10.1016/j.jhep.2014.11.020. View

Hernandes M, Cavalcanti S, Moreira D, de Azevedo Junior W, Lima Leite A . Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets. 2010; 11(3):303-14. DOI: 10.2174/138945010790711996. View

Xu Y, Luo Q, Lin T, Zeng Z, Wang G, Zeng D . U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways. PLoS One. 2014; 9(12):e113479. PMC: 4259312. DOI: 10.1371/journal.pone.0113479. View

10.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

11.

Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E . NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol. 2003; 39(6):932-9. DOI: 10.1016/s0168-8278(03)00393-3. View

12.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

13.

Halilbasic E, Steinacher D, Trauner M . Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. Dig Dis. 2017; 35(3):288-292. DOI: 10.1159/000454904. View

14.

Fickert P, Wagner M, Marschall H, Fuchsbichler A, Zollner G, Tsybrovskyy O . 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006; 130(2):465-81. DOI: 10.1053/j.gastro.2005.10.018. View

15.

Brossard D, El Kihel L, Clement M, Sebbahi W, Khalid M, Roussakis C . Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines. Eur J Med Chem. 2010; 45(7):2912-8. DOI: 10.1016/j.ejmech.2010.03.016. View

16.

Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J . Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother. 2018; 68(3):379-393. PMC: 11028337. DOI: 10.1007/s00262-018-2283-0. View

17.

Choi Y, Im E, Suh H, Jin Y, Yoo Y, Kim N . Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett. 2003; 199(2):157-67. DOI: 10.1016/s0304-3835(03)00351-3. View

18.

Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A . Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; . DOI: 10.1002/ijc.33588. View

19.

Im E, Choi S, Suh H, Choi Y, Yoo Y, Kim N . Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF-kappaB-dependent process in human cervical carcinoma cells. Cancer Lett. 2005; 229(1):49-57. DOI: 10.1016/j.canlet.2004.11.055. View

20.

Khare S, Mustafi R, Cerda S, Yuan W, Jagadeeswaran S, Dougherty U . Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer. 2008; 60(3):389-400. DOI: 10.1080/01635580701883003. View